Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase following Successful Thrombectomy in Patients with Large Vessel Occlusion: A Phase 1/2 Randomized Clinical Trial

Study design

The Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase following Successful Thrombectomy in Patients with Large Vessel Occlusion (DATE) is an open-label, randomized, multicenter, Phase Ib/IIa clinical trial designed to identify a dose of intra-arterial tenecteplase following successful EVT in patients with acute ischemic stroke due to LVO that shows sufficient evidence of safety and efficacy to advance to a pivotal trial. In designing this protocol, we adhered to the SPIRIT reporting guidelines¹³ for clarity and consistency. The DATE trial will be divided into two parts: the first part (Phase Ib) is a pilot dose-escalation safety study, and the second part (Phase IIa) is an exploratory study to assess the safety and potential efficacy of adjunctive intra-arterial tenecteplase after successful EVT in patients with LVO stroke at two different doses. After the completion of Phase Ib, a data safety monitoring board (DSMB) unblinded to study groups will select 2 doses (A or B) to be tested in Phase IIa according to the initial safety results.

Dose Escalation (Phase Ib)

This is a dose escalation trial. During this phase, participants will receive intra-arterial administration of increasing doses of tenecteplase after successful EVT. Patients will be treated with up to 4 escalating dose levels: 0.03125 mg/kg (1/8 i.v dose), 0.0625 mg/kg (1/4 i.v dose),0.125 mg/kg (1/2 i.v dose), and 0.1875 mg/kg (3/4 i.v dose).

According to the Chinese Acute Anterior Circulatory Ischemic Stroke Endovascular Treatment Registry Study, 13.8% of patients experienced symptomatic intracranial hemorrhage (sICH) within 24 hours of receiving EVT.¹⁴ Using sample sizes typical for dose escalation phase I clinical trials^15,16, we will use a 14+8 design scheme with sICH occurrence within 24 hours after EVT as the dose-limiting toxicity. At each tier, 14 patients will initially be enrolled. If fewer than 2 of 14 subjects develop sICH, the trial will advance to the next tier. If 2 of the 14 develop sICH, 8 more patients will be enrolled at that dose. If 0-1 of the additional 8 patients develops sICH, the trial will advance to the next tier. If 2 of the additional 8 patients develops sICH or 3 of the first 14 develop sICH, that dose will be deemed not tolerated and the immediately preceding dose will be the estimated maximum tolerated dose. The chart is shown in Figure 1.

• Download figure
• Open in new tab

Figure 1.

Flow chart for the Phase I of the DATE trial.

Dose Expansion (Phase IIa)

Two doses (A and B) will be chosen by the DSMB and investigators jointly according to the results in Phase Ib. In Phase II, a total of 157 new patients will be enrolled, with 46 patients assigned to the dose A group, 46 patients assigned to the dose B group, and an additional 65 patients allocated to the control group.

During this phase, 3 arms will be studied and patients will be randomized with stratification allocation according to two strata: patient age (<70 vs ≥ 70 years), and admission NIHSS score (< 15 vs ≥ 15), to receive 1 of the 2 selected doses of tenecteplase, or to the control group in a 1:1:√2 ratio, which in turn yields probabilities of assignment of 0.293, 0.293, and 0.414, respectively. Patients will be randomly assigned by using a real-time internet-based system. This process is automated which allows for concealment of the sequence of allocation.

Objectives

The primary objective of this study is to preliminarily assess the safety and efficacy of adjunctive intra-arterial tenecteplase at different doses following successful EVT in patients with acute ischemic stroke due to LVO to determine the promising dose to advance to a pivotal trial. Outcome: The study is designed to have two parts with different outcomes.

Dose Escalation (Phase Ib)

• Primary outcome: The primary outcome is sICH within 24 hours.

• Secondary outcome:

  1. 90-day modified mRS score 0-1 (%);

  2. Proportion of patients with functional independence (mRS score 0 to 2) at 90 days;

  3. Level of disability (ordinal distribution of mRS scores) at 90 days;

  4. Favorable shift in reperfusion on the eTICI score after intra-arterial tenecteplase thrombolysis therapy. All post-EVT, pre-IA and final post-IA final, angiograms will be scored at a core lab by central and blinded reviewers using the eTICI and classified as eTICI2b, eTICI2c, and eTICI3. The post treatment angiographies will be scored using the eTICI and classified as “improved”, “worsened” or “unchanged” with regard to the pre-IA infusion eTICI score.

  5. The change from baseline of the NIHSS score to 5–7 days or discharge if earlier;

  6. EQ-5D-3L at 90 days;

  7. Mortality within 90 days.

Dose Expansion (Phase IIa)

• Primary outcome: The primary outcome will be the proportion of patients with a nondisabled outcome (mRS score of 0 or 1) at 90 (±14) days. Primary outcome assessments will be performed at 90 (±14) days by two independent, certified physicians who are blinded to the treatment details. To maintain the reliability, accessibility, and traceability of the mRS score, we will retain a video or audio records of the 90-day follow-up for all patients. If video or audio recordings are unavailable, outcomes will be determined in-person by certified local investigators, who will be also unaware of the treatment assignment.

• Secondary outcomes:

  1. Proportion of patients with functional independence (mRS score 0 to 2) at 90 days;

  2. Level of disability (ordinal distribution of mRS scores) at 90 days;

  3. Favorable shift in eTICI score after intra-arterial tenecteplase thrombolysis therapy;

  4. The change of the NIHSS score from baseline to 5–7 days or discharge;

  5. EQ-5D-3L at 90 days;

  6. sICH rate within 24 hours;

  7. Mortality within 90 days.

Inclusion and exclusion criteria Inclusion criteria

1. Age ≥18 years;

2. Time from last known well within 24 hours;

3. Large vessel occlusive stroke in the anterior circulation confirmed by computed tomography angiography/magnetic resonance angiography, including intracranial segment of the internal carotid artery, first or second segment of the middle cerebral artery;

4. Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 based on non-contrast computed tomography;

5. National Institutes of Health Stroke Scale (NIHSS) score ≥ 6;

6. Successful endovascular thrombectomy (eTICI 2b-3);

7. Total pass numbers of thrombectomy procedure ≤ 3;

8. Written informed consent signed by patient or their family member.

Exclusion criteria

1. NIHSS score ≥ 25;

2. Intracranial hemorrhage confirmed by computed tomography or magnetic resonance imaging;

3. Treated by intravenous thrombolysis;

4. Prestroke mRS score ≥ 2.

5. Intraprocedural digital subtraction angiography suggests vessel penetration, dissection, or extravasation of contrast medium;

6. Pregnant or lactating patients;

7. Allergic to contrast agent or Tenecteplase;

8. Systolic pressure greater than 185 mmHg or diastolic pressure greater than 110 mmHg despite blood pressure lowering treatment;

9. Genetic or acquired bleeding disposition with anticoagulation factor deficiency or already taking oral anticoagulants within 48 hours and INR > 1.7;

10. Blood glucose < 2.8 mmol/L (50 mg/dl) or > 22.2 mmol/L (400 mg/dl), platelets < 90*10^9/L;

11. History of bleeding in the last 1 month (gastrointestinal and urinary tract bleeding);

12. Patients on chronic hemodialysis and severe renal insufficiency (glomerular filtration rate < 30 ml/min or blood creatinine > 220 μmol/L [2.5mg/dl]);

13. Any terminal illness with a life expectancy of less than 6 months;

14. Intracranial aneurysm, arteriovenous malformation;

15. Brain tumor with occupying mass effect on imaging;

16. Puncture to reperfusion time > 90 min;

17. Current participation in another clinical trial;

18. Unlikely to be available for 90-day follow-up.

Participating center eligibility

To qualify for participation in this trial, study centers will be mandated to have performed a minimum of 50 endovascular procedures each year. Additionally, all neurointerventionists involved will be required to have over five years of experience in cerebrovascular interventions, along with a track record of having performed at least 30 cases of mechanical thrombectomy using stent retriever devices annually.

Enrollment

Before initiating any procedure, participants or their legally authorized representatives will be provided with comprehensive oral and written information regarding the study, encompassing its objectives, potential risks, and anticipated benefits. Subsequently, they will be required to give their informed consent.

All individuals who fulfill the specified eligibility criteria are eligible for enrollment in the DATE clinical trial.

Study Intervention

Eligible patients assigned to the tenecteplase group will undergo an infusion of intra-arterial tenecteplase with the assigned dose. This infusion will be administered through a distal access catheter or microcatheter positioned proximal to the initially occluded artery. Patients allocated to the control group will terminate the procedure without further intraarterial thrombolysis.

All enrolled patients should be monitored in the acute stroke unit and can be admitted to the intensive care unit if necessary. All enrolled patients will undergo standardized medical treatment management and subsequent secondary preventive medication according to the Chinese Guidelines for Endovascular Treatment of Acute ischemic Stroke 2018.¹⁷

Blinding and masking

Each participating site will allocate one or more physicians to perform follow-up evaluations at 24-hour intervals, between five to seven days post-treatment, or at the time of discharge if it occurs sooner, along with a 90-day assessment. It is imperative that these physicians are not involved in the subject’s initial treatment to ensure their blinding to the treatment assignment.

Data safety monitoring board

The independent Data and Safety Monitoring Committee (DSMB) is responsible for reviewing the aggregated data and determining the study safety endpoints. The DSMB regularly reviews the study data added during the trial and advises the sponsor on the continued safety of the subjects and those not yet included in the study. The DSMB advises on the continued effectiveness and scientific value of the study.

Sample size estimates

Statistical analyses

Continuous variables will be summarized with the median, the inter-quartile range, the minimum, and the maximum. Categorical variables will be summarized with counts and percentages. Patient compliance with eligibility criteria and treatment administration, major protocol non-compliance, patient withdrawal and the reason for withdrawal (e.g., adverse event, protocol non-compliance, lost to follow up, failed to return, consent withdrawal, and other reasons) and assignment to each analysis population will be summarized using appropriate statistics by treatment arms. The statistical results of outcome analyses will be provided with point estimates of treatment differences with 95% confidence intervals (CIs).

The primary outcome in both phase Ib and IIa will be analyzed using generalized linear models from which a risk ratio with its 95% CI will be estimated as a measurement of treatment effect. The secondary outcomes and safety outcomes (binary, continuous and ordinal) will be analyzed using generalized linear models. For non-normal continuous outcome, a win ratio will be estimated as a measurement of treatment effect. A pooled analysis that combines the phase Ib and phase IIa will be performed as supportive analysis. The primary data analyses will adhere to the intention-to-treat principle. Additionally, per-protocol analyses will be conducted as supplementary analyses.

All statistical analyses will be described in detail in the statistical analysis plan which will be finalized before the study database lock, and will be performed using SAS version 9.4 (SAS Institute) and R version 4.4.0 or higher (R Foundation for Statistical Computing). The reporting of trial results will conform to the Consolidated Standards of Reporting Trials guidelines for randomized trials.

Ethical considerations

The study adheres to the ethical guidelines outlined in the Declaration of Helsinki. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of the Army Medical University and all participating centers. Any modifications to the trial protocol will only be executed after obtaining further approval from the ethics committee.